ArticleEuropean journal of clinical pharmacology2018
Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants.
Article in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Systematic review and scoring-based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children.British journal of clinical pharmacology · 2026Pooled it
- Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review.Clinical pharmacokinetics · 2021Pooled it
- Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates.Drugs in R&D · 2020Trial
- Association between vancomycin trough concentration monitoring and gestational age in neonates: a single-center, retrospective observational study.BMC pediatrics · 2026Observational
- Antibiotic Therapy for the Prevention and Treatment of Neonatal Sepsis.Clinics in perinatology · 2026Review
- Vancomycin Therapeutic Drug Monitoring, Clinical Outcomes and Population Pharmacokinetic Model Evaluation in Neonates.Children (Basel, Switzerland) · 2026Article
- Advances in Pediatric Therapeutic Drug Monitoring.Pediatrics · 2026Review
- Prediction of Vancomycin Area Under the Curve With Trough Concentrations Only: Performance Evaluation of Pediatric Population Pharmacokinetic Models.The Journal of infectious diseases · 2025Article
- Machine learning approach for personalized vancomycin steady-state trough concentration prediction: a superior approach over Bayesian population pharmacokinetic model.Frontiers in pharmacology · 2025Article
- A Review of Vancomycin, Gentamicin, and Amikacin Population Pharmacokinetic Models in Neonates and Infants.Clinical pharmacokinetics · 2025Review
- External evaluation of neonatal vancomycin population pharmacokinetic models: Moving from first-order equations to Bayesian-guided therapeutic monitoring.Pharmacotherapy · 2024Article
- Optimizing vancomycin dosing in pediatrics: a machine learning approach to predict trough concentrations in children under four years of age.International journal of clinical pharmacy · 2024Observational
- Antibiotics, Analgesic Sedatives, and Antiseizure Medications Frequently Used in Critically Ill Neonates: A Narrative Review.Children (Basel, Switzerland) · 2024Review
- Prospective validation of a model-informed precision dosing tool for vancomycin treatment in neonates.Antimicrobial agents and chemotherapy · 2024Article
- Personalized application of antimicrobial drugs in pediatric patients with augmented renal clearance: a review of literature.European journal of pediatrics · 2024Review
- Vancomycin population pharmacokinetics analysis in Chinese paediatric patients with varying degrees of renal function and ages: development of new practical dosing recommendations.The Journal of antimicrobial chemotherapy · 2023Article
- Optimizing Vancomycin Dosing and Monitoring in Neonates and Infants Using Population Pharmacokinetic Modeling.Antimicrobial agents and chemotherapy · 2022Article
- Vancomycin in neonatal sepsis: predictive performance of a Chinese neonatal population pharmacokinetic model and clinical efficacy evaluation.European journal of hospital pharmacy : science and practice · 2022Article
- An Update on Population Pharmacokinetic Analyses of Vancomycin, Part II: In Pediatric Patients.Clinical pharmacokinetics · 2022Review
- The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients.Pharmacology research & perspectives · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo develop a population pharmacokinetic (PK) model for vancomycin in Chinese neonates and infants less than 2 months of age (young infants) with a wide gestational age range, in order to determine the appropriate dosing regimen for this population.
methodsWe performed a retrospective chart review of patients from the neonatal intensive care unit (NICU) at Children's Hospital of Fudan University to identify neonates and young infants treated with vancomycin from May 2014 to May 2017. Vancomycin concentrations and covariates were utilized to develop a one-compartment model with first-order elimination. The predictive performance of the final model was assessed by both internal and external evaluation, and the relationship between trough concentration and AUC
resultsThe analysis included a total of 330 concentration-time data points from 213 neonates and young infants with gestational age (GA) and body weight of 25-42 weeks and 0.88-5.1 kg, respectively. Body weight, postmenstrual age (PMA) and serum creatinine level were found to be important factors explaining the between-subject variability in vancomycin PK parameters for this population. Both internal and external evaluation supported the prediction of the final vancomycin PK model. The typical population parameter estimates of clearance and distribution volume for an infant weighing 2.73 kg with a PMA of 39.8 weeks and serum creatinine of 0.28 mg/dL were 0.103 L/h/kg and 0.58 L/kg, respectively. Although vancomycin serum trough concentrations were predictive of the AUC, considerable variability was observed in the achievement of an AUC
conclusionsThe PK parameters for vancomycin in Chinese infants younger than 2 months of age were estimated using the model developed herein. This model has been used to predict individualized dosing regimens in this vulnerable population in our hospital. A large external evaluation of our model will be conducted in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.